Novartis AG ADR (NVS)vsRigel Pharmaceuticals Inc (RIGL)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
RIGL
Rigel Pharmaceuticals Inc
$29.93
-1.06%
HEALTHCARE · Cap: $593.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 18774% more annual revenue ($56.58B vs $299.77M). RIGL leads profitability with a 121.5% profit margin vs 23.9%. RIGL trades at a lower P/E of 1.7x. RIGL earns a higher WallStSmart Score of 65/100 (B-).
NVS
Hold49
out of 100
Grade: D+
RIGL
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+87.7%
Fair Value
$283.28
Current Price
$29.93
$253.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 91 in profit
Keeps 122 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Strong operational efficiency at 20.2%
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Smaller company, higher risk/reward
Earnings declined 30.2%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 121.5% and operating margin at 20.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
NVS profiles as a declining stock while RIGL is a mature play — different risk/reward profiles.
RIGL carries more volatility with a beta of 1.18 — expect wider price swings.
RIGL is growing revenue faster at 10.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
RIGL scores higher overall (65/100 vs 49/100), backed by strong 121.5% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?